Company attributes
Other attributes
Calico (California Life Company) is a biotechnology company owned by Alphabet researching and developing therapies to increase human lifespan that is headquartered in South San Francisco, California and was founded in 2013 by Arthur Levinson. During the companies launch announcement the CEO of Google at the time, Larry Page, made the following statement about Calico's founder Arthur Levinson:
Illness and aging affect all our families. With some longer term, moonshot thinking around healthcare and biotechnology, I believe we can improve millions of lives. It’s impossible to imagine anyone better than Art—one of the leading scientists, entrepreneurs and CEOs of our generation—to take this new venture forward.
On November 28, 2019 Calico announced it will be collaborating with the University of Pennsylvania's Translational Medicine and Therapeutics. Dr. Garret FitzGerald will lead the collaboration project which is to monitor the progress of the clinical trials of Calico's drug candidates, and to identify collaboration opportunities for scientists at the University of Pennsylvania to work with Calico on creating therapies for anti-ageing and age-related diseases.
The following list contains the peer-reviewed research papers published by scientists working with Calico:
- eIF2B activator prevents neurological defects caused by a chronic integrated stress response
- A new experimental platform facilitates assessment of the transcriptional and chromatin landscapes of aging yeast
- Estimates of the Heritability of Human Longevity Are Substantially Inflated due to Assortative Mating
- A window into extreme longevity; the circulating metabolomic signature of the naked mole-rat, a mammal that shows negligible senescence
- The small molecule ISRIB rescues the stability and activity of Vanishing White Matter Disease eIF2B mutant complexes
- Common and divergent features of galactose-1-phosphate and fructose-1-phosphate toxicity in yeast
- Naked mole-rat mortality rates defy Gompertzian laws by not increasing with age
- A lysosomal switch triggers proteostasis renewal in the immortal C. elegans germ lineage
- The naked mole-rat exhibits an unusual cardiac myofilament protein profile providing new insights into heart function of this naturally subterranean rodent
- The protein kinase MBK-1 contributes to lifespan extension in daf-2 mutant and germline-deficient Caenorhabditis elegans
- How a mutation that slows aging can also disproportionately extend end-of-life decrepitude
- Extended Postnatal Brain Development in the Longest-Lived Rodent: Prolonged Maintenance of Neotenous Traits in the Naked Mole-Rat Brain
- Deep Proteome Analysis Identifies Age-Related Processes in C. elegans
- Unraveling the message: insights into comparative genomics of the naked mole-rat
- Reversible Age-Related Phenotypes Induced during Larval Quiescence in C. elegans
- Mechanisms regulating proteostasis are involved in sympatric speciation of the blind mole rat, Spalax galili
- From yeast to human: exploring the comparative biology of methionine restriction in extending eukaryotic life span.
- Sympatric speciation revealed by genome-wide divergence in the blind mole rat Spalax
- Untangling Aging Using Dynamic, Organism-Level Phenotypic Networks
- The future of humans as model organisms
- Challenges in validating candidate therapeutic targets in cancer
- A three-drug combination to treat BRAF-mutant cancers
- The Upsides and Downsides of Organelle Interconnectivity
- Cutting back on the essentials: Can manipulating intake of specific amino acids modulate health and lifespan?
- TORquing metabolic reprogramming in cancer cells
- Communication in Drug Development: “Translating” Scientific Discovery
- Cancer: Bet on drug resistance.
- From Cancer Genomics to Precision Oncology—Tissue’s Still an Issue
